Kinase inhibitors in the treatment of renal cell carcinoma

被引：32

作者：

Larkin, James M. G. ^{[1
]}

Eisen, Tim ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 60卷 / 03期

关键词：

renal cell carcinoma; metastatic; systemic therapy; kinase inhibition; targeted drugs;

D O I：

10.1016/j.critrevonc.2006.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy confers a small but significant overall survival advantage in metastatic renal cell carcinoma (RCC) but a need exists to develop more effective systemic therapies. Angiogenesis has a key role in the pathophysiology of renal cell carcinoma and vascular endothelial growth factor (VEGF) is an important mediator of this process. Sunitimb, sorafenib and axitinib are new agents which belong to a class of drugs called kinase inhibitors and inhibit the VEGF, platelet-derived growth factor (PDGF) and c-KIT receptor tyrosine kinases. Ternsirolimus inhibits the mammalian target of rapamycin (mTOR). All these agents have shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients generally pretreated with immunotherapy, whilst prolonged progression-free survival in a phase 3 study has been reported with sorafenib in comparison with placebo. Further phase 3 trials are recruiting and the combination of kinase inhibitors with other therapies is under investigation. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：216 / 226

页数：11

共 97 条

[91] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

[92] The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia [J].

Wolff, NC ;

Richardson, JA ;

Egorin, M ;

Ilaria, RL .

BLOOD, 2003, 101 (12) :5010-5013

[93] FAILURE OF CYTOTOXIC CHEMOTHERAPY, 1983-1988, AND THE EMERGING ROLE OF MONOCLONAL-ANTIBODIES FOR RENAL-CANCER [J].

YAGODA, A ;

BANDER, NH .

UROLOGIA INTERNATIONALIS, 1989, 44 (06) :338-345

[94] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].

Yang, JC ;

Haworth, L ;

Sherry, RM ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Steinberg, SM ;

Chen, HX ;

Rosenberg, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434

[95] Molecular classification of papillary renal cell carcinoma [J].

Yang, XMJ ;

Tan, MN ;

Kim, HL ;

Ditlev, JA ;

Betten, MW ;

Png, CE ;

Kort, EJ ;

Futami, K ;

Furge, KA ;

Takahashi, M ;

Kanayama, H ;

Tan, PH ;

Teh, BS ;

Luan, CY ;

Wang, K ;

Pins, M ;

Tretiakova, M ;

Anema, J ;

Kahnoski, R ;

Nicol, T ;

Stadler, W ;

Vogelzang, NG ;

Amato, R ;

Seligson, D ;

Figlin, R ;

Belldegrun, A ;

Rogers, CG ;

Teh, BT .

CANCER RESEARCH, 2005, 65 (13) :5628-5637

[96]

Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569

[97] Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg [J].

Zalcberg, JR ;

Verweij, J ;

Casali, PG ;

Le Cesne, A ;

Reichardt, P ;

Blay, JY ;

Schlemmer, M ;

Van Glabbeke, M ;

Brown, M ;

Judson, IR .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) :1751-1757

← 1 2 3 4 5 6 7 8 9 10 →